Preferred Label : Lorlatinib;
NCIt synonyms : 7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile; 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile,
7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-;
NCIt definition : An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic
lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.
Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The
kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually
inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition,
PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor
superfamily and plays an important role in nervous system development; ALK dysregulation
and gene rearrangements are associated with a series of tumors. ROS1, overexpressed
in certain cancer cells, plays a key role in cell growth and survival of cancer cells.;
UNII : OSP71S83EU;
InChIKey : IIXWYSCJSQVBQM-LLVKDONJSA-N;
CAS number : 1454846-35-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1454846-35-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Lorbrena; Lorviqua;
Molecule name : PF-06463922;
Codes from synonyms : 314;
Origin ID : C113655;
UMLS CUI : C4080091;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
